Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYGN Myriad Genetics	$6.02 +3.3%	$5.15	$3.76 ▼ $29.30	$560.13M	1.89	2.48 million shs	1.01 million shs
RIGL Rigel Pharmaceuticals	$41.50 -1.2%	$24.11	$12.00 ▼ $43.72	$744.39M	1.21	808,428 shs	895,255 shs
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A
ZBIO Zenas BioPharma	$17.10 +1.0%	$13.26	$5.83 ▼ $26.25	$720.08M	N/A	160,623 shs	231,632 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYGN Myriad Genetics	0.00%	+5.43%	+29.46%	+53.96%	-78.45%
RIGL Rigel Pharmaceuticals	0.00%	+5.04%	+103.13%	+119.00%	+231.47%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ZBIO Zenas BioPharma	0.00%	+1.66%	+4.78%	+49.61%	+1,709,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYGN Myriad Genetics	3.6024 of 5 stars	3.1	2.0	4.1	2.3	1.7	0.0
RIGL Rigel Pharmaceuticals	1.6689 of 5 stars	1.2	1.0	0.0	2.6	1.7	3.1
SPPI Spectrum Pharmaceuticals	0.3845 of 5 stars	0.0	0.0	4.7	0.0	0.0	0.6
ZBIO Zenas BioPharma	1.4764 of 5 stars	3.5	0.0	0.0	1.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYGN Myriad Genetics	2.21	Hold	$12.45	106.89% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-7.95% Downside
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A
ZBIO Zenas BioPharma	3.00	Buy	$36.67	114.42% Upside

Current Analyst Ratings Breakdown

Latest SPPI, RIGL, ZBIO, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYGN Myriad Genetics	$832.90M	0.67	$1.00 per share	6.03	$4.17 per share	1.44
RIGL Rigel Pharmaceuticals	$179.28M	4.15	$1.08 per share	38.47	$4.57 per share	9.08
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87
ZBIO Zenas BioPharma	$5M	144.02	N/A	N/A	$5.69 per share	3.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	11/6/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.67	39.52	N/A	36.51%	438.89%	57.03%	11/6/2025 (Estimated)
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A
ZBIO Zenas BioPharma	-$156.99M	-$3.55	N/A	∞	N/A	N/A	-59.21%	-50.56%	11/11/2025 (Estimated)

Latest SPPI, RIGL, ZBIO, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	-$1.25	-$0.23	-$1.25	$5.00 million	N/A
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYGN Myriad Genetics	N/A	1.42	1.28
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38
ZBIO Zenas BioPharma	N/A	5.23	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MYGN Myriad Genetics	99.02%
RIGL Rigel Pharmaceuticals	66.23%
SPPI Spectrum Pharmaceuticals	21.67%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
MYGN Myriad Genetics	2.40%
RIGL Rigel Pharmaceuticals	9.48%
SPPI Spectrum Pharmaceuticals	2.70%
ZBIO Zenas BioPharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MYGN Myriad Genetics	2,700	93.05 million	90.81 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable
ZBIO Zenas BioPharma	N/A	42.11 million	35.16 million	N/A

SPPI, RIGL, ZBIO, and MYGN Headlines

Recent News About These Companies

Zenas BioPharma (NASDAQ:ZBIO) Trading Down 7.2% - Here's What Happened

August 21 at 4:21 PM | marketbeat.com

We Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth Carefully

August 20, 2025 | finance.yahoo.com

Zenas BioPharma (NASDAQ:ZBIO) Trading 8.1% Higher - Should You Buy?

August 20, 2025 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Zenas BioPharma

August 17, 2025 | marketbeat.com

What is Wedbush's Estimate for Zenas BioPharma Q3 Earnings?

August 17, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to Sell at Wall Street Zen

August 17, 2025 | marketbeat.com

Wedbush Has Pessimistic View of Zenas BioPharma Q3 Earnings

August 17, 2025 | americanbankingnews.com

Zenas BioPharma Q3 EPS Forecast Decreased by HC Wainwright

August 16, 2025 | americanbankingnews.com

Zenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on Thursday

August 15, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

August 14, 2025 | marketbeat.com

Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit

August 13, 2025 | msn.com

Zenas BioPharma Reports Q2 2025 Financial Results

August 13, 2025 | tipranks.com

Zenas BioPharma expects cash to fund operations into Q4 of 2026

August 12, 2025 | msn.com

Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year

August 12, 2025 | msn.com

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 12, 2025 | globenewswire.com

44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.

August 9, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?

August 6, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?

August 5, 2025 | marketbeat.com

3 Highly Shorted Stocks That Could Be the Next Wall Street Sensations

August 2, 2025 | msn.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's Why

July 29, 2025 | marketbeat.com

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

July 28, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPPI, RIGL, ZBIO, and MYGN Company Descriptions

Myriad Genetics NASDAQ:MYGN

$6.02 +0.19 (+3.26%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.00 -0.02 (-0.33%)

As of 08/22/2025 07:33 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Rigel Pharmaceuticals NASDAQ:RIGL

$41.50 -0.49 (-1.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$41.38 -0.13 (-0.30%)

As of 08/22/2025 07:52 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Zenas BioPharma NASDAQ:ZBIO

$17.10 +0.17 (+1.00%)

As of 08/22/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time